MannKind Corporation (NASDAQ: MNKD) is 32.75% higher on its value in year-to-date trading and has touched a low of $0.91 and a high of $6.25 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MNKD stock was last observed hovering at around $3.92 in the last trading session, with the day’s gains setting it 0.24% off its average median price target of $6.50 for the next 12 months. It is also 48.0% off the consensus price target high of $8.00 offered by 5 analysts, but current levels are 16.8% higher than the price target low of $5.00 for the same period.
Currently trading at $4.16, the stock is 12.15% and -2.95% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 9.41 million and changing 5.99% at the moment leaves the stock 51.24% off its SMA200. MNKD registered 334.62% gain for a year compared to 6-month gain of 121.01%. The firm has a 50-day simple moving average (SMA 50) of $4.2521 and a 200-day simple moving average (SMA200) of $3.2371.
The stock witnessed a 14.78% loss in the last 1 month and extending the period to 3 months gives it a 23.66%, and is 11.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.57% over the week and 7.93% over the month.
MannKind Corporation (MNKD) has around 241 employees, a market worth around $968.90M and $65.10M in sales. Profit margin for the company is -87.90%. Distance from 52-week low is 356.94% and -33.52% from its 52-week high. The company has generated returns on investments over the last 12 months (82.50%).
MannKind Corporation (MNKD) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for MannKind Corporation (MNKD) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.40, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
MannKind Corporation is expected to release its quarterly report on 08/09/2021 and quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $15.66M over the same period.The EPS is expected to grow by 3.10% this year, but quarterly earnings will post 16.90% year-over-year. Quarterly sales are estimated to grow 5.90% in year-over-year returns.
MannKind Corporation (MNKD) Top Institutional Holders
196 institutions hold shares in MannKind Corporation (MNKD), with 11.47M shares held by insiders accounting for 4.64% while institutional investors hold 32.38% of the company’s shares. The shares outstanding are 243.78M, and float is at 236.34M with Short Float at 12.19%. Institutions hold 30.87% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 17.98 million shares valued at $56.26 million. The investor’s holdings represent 7.27% of the MNKD Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 12.29 million shares valued at $38.47 million to account for 4.97% of the shares outstanding. The other top investors are State Street Corporation which holds 8.85 million shares representing 3.58% and valued at over $27.69 million, while FMR, LLC holds 1.51% of the shares totaling 3.73 million with a market value of $11.68 million.
MannKind Corporation (MNKD) Insider Activity
A total of 6 insider transactions have happened at MannKind Corporation (MNKD) in the last six months, with sales accounting for 1 and purchases happening 5 times. The most recent transaction is an insider purchase by Castagna Michael ,the company’sChief Executive Officer. SEC filings show that Castagna Michael bought 3,000 shares of the company’s common stock on Mar 05 at a price of $3.38 per share for a total of $10140.0. Following the purchase, the insider now owns 3000.0 shares.
MannKind Corporation disclosed in a document filed with the SEC on Jan 31 that Castagna Michael (Chief Executive Officer) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Jan 31 and was made at $1.33 per share for $6650.0. Following the transaction, the insider now directly holds 1.12 million shares of the MNKD stock.
Still, SEC filings show that on Jan 31, Tross Stuart A (Chief People & Workpl Officer) acquired 5,000 shares at an average price of $1.33 for $6650.0. The insider now directly holds 481,991 shares of MannKind Corporation (MNKD).
MannKind Corporation (MNKD): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 35.79% up over the past 12 months and Pfizer Inc. (PFE) that is 20.64% higher over the same period. Novo Nordisk A/S (NVO) is 13.24% up on the 1-year trading charts. Short interest in the company’s stock has risen 42.57% from the last report on Feb 11, 2021 to stand at a total of 16.54 million short shares sold with a short interest ratio of 3.69.